fondaparinux fondaparinux fondaparinux (trade name arixtra) is an anticoagulant medication chemically related to low molecular weight heparins. it is marketed by glaxosmithkline. a generic version developed by alchemia is marketed within the us by dr. reddy's laboratories. fondaparinuxclinical datatrade namesarixtraahfs/drugs.commonographlicense data eu ema: by inn us dailymed: fondaparinux routes ofadministrationsubcutaneousatc codeb01ax05 (who) legal statuslegal status au: s4 (prescription only) uk: pom (prescription only) us: ℞-only eu: rx-only pharmacokinetic databioavailabilityn/aprotein binding94%metabolismrenally excreted unchangedelimination half-life17-21 hoursidentifierscas number104993-28-4 ydecasodium salt: 114870-03-0 ypubchem cid636380drugbankdb00569 ychemspider552174 yuniij177fow5jldecasodium salt: x0q6n9usoz ychemblchembl1201202 ncomptox dashboard (epa)dtxsid10146903 chemical and physical dataformulac31h43n3na10o49s8molar mass1728.03 g·mol−13d model (jsmol)interactive image smiles ..........s(=o)(=o)n5(o)(o)(cos()(=o)=o)o5o1(o)(o)(o1c()=o)o4(cos()(=o)=o)o(o3(o)(os()(=o)=o)(o2(o)(ns()(=o)=o)(oc)o2cos()(=o)=o)o3c()=o)(ns()(=o)=o)4os()(=o)=o inchi inchi=1s/c31h53n3o49s8.10na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40h,2-4h2,1h3,(h,41,42)(h,43,44)(h,45,46,47)(h,48,49,50)(h,51,52,53)(h,54,55,56)(h,57,58,59)(h,60,61,62)(h,63,64,65)(h,66,67,68);;;;;;;;;;/q;10*+1/p-10/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1 ykey:xekstynijlddaz-jasswcpgsa-d y ny (what is this?) (verify) medical uses clinically, it is used for the prevention of deep vein thrombosis in patients who have had orthopedic surgery as well as for the treatment of deep vein thrombosis and pulmonary embolism. fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long-term mortality and morbidity. it has been investigated for use in conjunction with streptokinase. comparison to other agents one potential advantage of fondaparinux over lmwh or unfractionated heparin is that the risk for heparin-induced thrombocytopenia (hit) is substantially lower. furthermore, there have been case reports of fondaparinux being used to anti-coagulate patients with established hit as it has no affinity for pf4. however, its renal excretion precludes its use in patients with renal dysfunction. unlike direct factor xa inhibitors, it mediates its effects indirectly through antithrombin iii, but unlike heparin, it is selective for factor xa. pharmacology mechanism of action